Teva fires back at GSK again over potential 'skinny' label SCOTUS case
Teva on Wednesday fired back at GSK after the UK-based drugmaker sought to squash Teva’s attempt to get its “skinny” label case overturned by the US Supreme Court.
Teva filed a reply to GSK on Wednesday, slamming the firm’s claims around these label carve-outs, which generic drugmakers use frequently to get competition on the market before all the patented indications of the reference product can be challenged.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
